Hanmi Pharmaceutical's Management Dispute and 60 Billion Won Lawsuit Triggered by Inheritance Tax Issues
Hanmi Pharmaceutical Group, a prominent South Korean pharmaceutical company, is undergoing a serious management dispute. This conflict began with the massive inheritance tax issues that the surviving family members had to face after the passing of the founder, the late Chairman Lim Sung-ki. The situation became complicated as family members disagreed on the future direction of the company.
The inheritance tax that the Hanmi Pharmaceutical family must pay is known to exceed approximately 460 billion won. This tax payment issue, which began in 2021, has become a significant economic burden for the family. In this process, deep conflicts arose among family members regarding the methods to resolve the inheritance tax and the company's management style.
Recently, this conflict has escalated into a large-scale lawsuit worth 60 billion won. Cracks have begun to appear in the 'four-party alliance' system of family members and stakeholders who initially seemed to be cooperating. As their interests diverged, it led to legal battles, casting further uncertainty over the future of Hanmi Pharmaceutical's management rights.
These internal disputes are creating anxiety about the company's future. The massive lawsuit and management battle could affect not only Hanmi Pharmaceutical's corporate image but also its stock price. Many investors and industry insiders are watching the situation with concern over how this incident will interfere with the company's research and development and business operations.
Ultimately, this situation at Hanmi Pharmaceutical clearly demonstrates how complex and difficult the inheritance tax issues and management succession processes of large South Korean corporations can be. Amidst family conflicts turning into legal battles, how Hanmi Pharmaceutical overcomes this crisis and achieves management stabilization is expected to be a crucial task ahead.